Zacks Research Estimates Neogen's Q2 Earnings (NASDAQ:NEOG)

Key Points

• Zacks Research raised Neogen’s Q2 2027 earnings estimate to $0.08 per share from $0.07, while forecasting full-year 2027 earnings of $0.25 per share and 2028 earnings of $0.29 per share.
• Neogen’s latest quarterly results exceeded expectations, with EPS of $0.09 versus the $0.06 consensus and revenue of $225.3 million versus $212.35 million, although revenue declined slightly year over year and the company reported a negative net margin.
• Analyst sentiment is mixed but improving: Piper Sandler upgraded the stock to “overweight,” while MarketBeat’s overall consensus remains “Hold” with an $11.67 price target. Institutional investors own 96.73% of Neogen’s shares.

Neogen Corporation (NASDAQ:NEOG - Free Report) - Equities research analysts at Zacks Research lifted their Q2 2027 earnings per share estimates for Neogen in a research note issued on Thursday, August 20th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.08 per share for the quarter, up from their prior forecast of $0.07. The consensus estimate for Neogen's current full-year earnings is $0.25 per share. Zacks Research also issued estimates for Neogen's Q3 2027 earnings at $0.06 EPS, Q4 2027 earnings at $0.07 EPS, Q1 2028 earnings at $0.05 EPS, Q3 2028 earnings at $0.07 EPS, Q4 2028 earnings at $0.09 EPS and FY2028 earnings at $0.29 EPS.

Neogen (NASDAQ:NEOG - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. The company had revenue of $225.30 million during the quarter, compared to the consensus estimate of $212.35 million. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The company's revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.82) earnings per share.

Other analysts also recently issued research reports about the stock. Piper Sandler raised shares of Neogen from a "neutral" rating to an "overweight" rating in a research report on Wednesday. Weiss Ratings raised shares of Neogen from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Neogen from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Neogen has a consensus rating of "Hold" and a consensus price target of $11.67.

Neogen Stock Performance

Neogen stock opened at $11.64 on Wednesday. The stock's 50 day moving average price is $10.31 and its 200 day moving average price is $9.84. The firm has a market capitalization of $2.54 billion, a PE ratio of -388.00, a price-to-earnings-growth ratio of 4.58 and a beta of 1.77. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.91 and a current ratio of 3.82. Neogen has a one year low of $4.90 and a one year high of $12.85.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NEOG. Huntington National Bank grew its stake in Neogen by 8.4% in the fourth quarter. Huntington National Bank now owns 13,552 shares of the company's stock valued at $95,000 after acquiring an additional 1,045 shares during the period. ProShare Advisors LLC boosted its position in shares of Neogen by 3.2% during the fourth quarter. ProShare Advisors LLC now owns 42,509 shares of the company's stock worth $297,000 after buying an additional 1,331 shares during the period. Evergreen Capital Management LLC boosted its position in Neogen by 12.3% during the 4th quarter. Evergreen Capital Management LLC now owns 13,753 shares of the company's stock worth $96,000 after acquiring an additional 1,504 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its stake in shares of Neogen by 10.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 17,837 shares of the company's stock worth $125,000 after acquiring an additional 1,638 shares in the last quarter. Finally, Values First Advisors Inc. grew its stake in shares of Neogen by 2.2% during the 1st quarter. Values First Advisors Inc. now owns 90,238 shares of the company's stock worth $838,000 after acquiring an additional 1,917 shares in the last quarter. Institutional investors and hedge funds own 96.73% of the company's stock.

Neogen Company Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen's product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source